Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial

BACKGROUND: The recombinant protein-based vaccine, NVX-CoV2373, demonstrated 89.7% efficacy against coronavirus disease 2019 (COVID-19) in a phase 3, randomized, observer-blinded, placebo-controlled trial in the United Kingdom. The protocol was amended to include a blinded crossover. Data to the end...

Descripción completa

Detalles Bibliográficos
Autores principales: Heath, Paul T, Galiza, Eva P, Baxter, David Neil, Boffito, Marta, Browne, Duncan, Burns, Fiona, Chadwick, David R, Clark, Rebecca, Cosgrove, Catherine A, Galloway, James, Goodman, Anna L, Heer, Amardeep, Higham, Andrew, Iyengar, Shalini, Jeanes, Christopher, Kalra, Philip A, Kyriakidou, Christina, Bradley, Judy M, Munthali, Chigomezgo, Minassian, Angela M, McGill, Fiona, Moore, Patrick, Munsoor, Imrozia, Nicholls, Helen, Osanlou, Orod, Packham, Jonathan, Pretswell, Carol H, San Francisco Ramos, Alberto, Saralaya, Dinesh, Sheridan, Ray P, Smith, Richard, Soiza, Roy L, Swift, Pauline A, Thomson, Emma C, Turner, Jeremy, Viljoen, Marianne Elizabeth, Fries, Louis, Cho, Iksung, McKnight, Irene, Glenn, Greg, Rivers, E Joy, Robertson, Andreana, Alves, Katia, Smith, Kathy, Toback, Seth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619635/
https://www.ncbi.nlm.nih.gov/pubmed/36210481
http://dx.doi.org/10.1093/cid/ciac803

Ejemplares similares

Ejemplares similares